PGNX Share Price

Open 10.65 Change Price %
High 10.75 1 Day -0.18 -1.69
Low 10.21 1 Week 0.82 8.52
Close 10.44 1 Month 1.55 17.44
Volume 2116643 1 Year 5.73 121.66
52 Week High 10.84
52 Week Low 3.80
PGNX Important Levels
Resistance 2 10.94
Resistance 1 10.73
Pivot 10.47
Support 1 10.15
Support 2 9.94
NASDAQ USA Most Active Stocks
SCHN 26.75 0.38%
SCHN 26.75 0.38%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
LLEN 0.02 100.00%
SPIR 0.02 100.00%
LOCM 0.09 50.00%
GALT 1.94 31.97%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AEHR 4.99 21.41%
BGMD 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LIWA 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Progenics Pharmaceuticals Inc. (NASDAQ: PGNX)

PGNX Technical Analysis 5
As on 21st Feb 2017 PGNX Share Price closed @ 10.44 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 6.47 & Strong Buy for SHORT-TERM with Stoploss of 9.11 we also expect STOCK to react on Following IMPORTANT LEVELS.
PGNX Target for February
1st Target up-side 9.75
2nd Target up-side 10.33
3rd Target up-side 10.91
1st Target down-side 8.09
2nd Target down-side 7.51
3rd Target down-side 6.93
PGNX Other Details
Segment EQ
Market Capital 99951264.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.progenics.com
PGNX Address
PGNX
777 Old Saw Mill River Road
Tarrytown, NY 10591
United States
Phone: 914-789-2800
Fax: 914-789-2817
Interactive Technical Analysis Chart Progenics Pharmaceuticals Inc. ( PGNX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Progenics Pharmaceuticals Inc.
PGNX Business Profile
Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers. In gastroenterology, its first commercial product is RELISTOR subcutaneous injection. Its principal product candidate is PSMA ADC, a fully human monoclonal antibody-drug conjugate directed against prostate specific membrane antigen, a protein found at high levels on the surface of prostate cancer cells and also on the neovasculature of a number of other types of solid tumors. In January 2013, the Company acquired Molecular Insight Pharmaceuticals, Inc.